Clinical trials
Follow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
Qianlieshutong
- Development stage
- Phase 4
- Lead developer
- Buchang Pharmaceuticals
- Modality
- Metabolically Activated Prodrugs → Prodrugs/Conditional Activator Small Molecules → Small Molecules, Classical Binding Small Molecules → Small Molecules
- Administration
- Oral
01
Overview
Qianlieshutong is a Chinese patent medicine (CPM) developed by Shaanxi Buchang Pharmaceutical, primarily used for the treatment of chronic prostatitis and benign prostatic hyperplasia (BPH). It is a multi-ingredient herbal formulation that includes extracts from *Phellodendron amurense*, *Smilax glabra*, *Coix lacryma-jobi*, and *Paeonia lactiflora*, among others. The therapeutic mechanism of Qianlieshutong involves anti-inflammatory, analgesic, and anti-bacterial activities, as well as the promotion of local blood circulation to reduce prostate congestion. It is frequently used in clinical practice in China, often in combination with alpha-blockers like tamsulosin to improve lower urinary tract symptoms (LUTS) and quality of life in patients with urological conditions.
- Brand names
- Qianlieshutong
- Other names
- Qianlieshutong capsuleQianlieshutong Jiaonang前列舒通胶囊
02
Targets
IL-6 (Interleukin 6)IL8 (C-X-C Motif Chemokine Ligand 8)TNFA (Tumor necrosis factor alpha (soluble))
Beyond the preview
Go deeper on Qianlieshutong.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Explore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Trace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Explore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Compare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Connect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on Qianlieshutong.